Time-dependent endpoints as predictors of overall survival in multiple myeloma

Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 13; no. 1; p. 122
Main Authors:	Félix, Jorge, Aragão, Filipa, Almeida, João M, Calado, Frederico J, Ferreira, Diana, Parreira, António B S, Rodrigues, Ricardo, Rijo, João F R
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 16-03-2013 BioMed Central
Subjects:	Aged Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Care and treatment Clinical trials Disease-Free Survival Economic models Estimates FDA approval Female Hematopoietic Stem Cell Transplantation Humans Male Medical research Medicine, Experimental Middle Aged Multiple myeloma Multiple Myeloma - mortality Multiple Myeloma - therapy Prognosis Randomized Controlled Trials as Topic Statistical methods Studies Transplantation, Homologous Variables United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman's rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7-3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1471-2407 1471-2407
DOI:	10.1186/1471-2407-13-122